Evaluation of Synbiotics in the Prevention of Ventilator-Associated Pneumonia: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial.

IF 1.7 Q2 MEDICINE, GENERAL & INTERNAL

International Journal of Preventive Medicine Pub Date : 2023-11-02 eCollection Date: 2023-01-01 DOI:10.4103/ijpvm.ijpvm_329_22

Faranak Kasiri, Rasool Soltani, Farzin Khorvash, Behrooz Ataei, Maryam Nasirian, Atousa Hakamifard

{"title":"Evaluation of Synbiotics in the Prevention of Ventilator-Associated Pneumonia: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial.","authors":"Faranak Kasiri, Rasool Soltani, Farzin Khorvash, Behrooz Ataei, Maryam Nasirian, Atousa Hakamifard","doi":"10.4103/ijpvm.ijpvm_329_22","DOIUrl":null,"url":null,"abstract":"Background: Ventilator-associated pneumonia (VAP) is one of the most common nosocomial infections. The role of probiotics in preventing VAP is still questionable. This study aimed at evaluating the effect of synbiotic FamiLact 2plus on the prevention of VAP in patients admitted to the intensive care unit (ICU).Methods: A total of 80 mechanically ventilated patients were included and divided into two groups of 40. Group 1 received FamiLact 2plus, and group 2 received placebo. The outcome variables were compared, including the incidence of VAP, the time interval between the onset of ventilation and VAP, the duration of mechanical ventilation, and the length of stay in the ICU.Results: VAP is documented in four patients (10%) in group 1 and 11 patients (27.5%) in group 2 (P = 0.045). The length of stay in the ICU in group 1 was significantly shorter than in group 2, and the time interval between the start of intubation and the onset of VAP in group 1 was longer than in the placebo group. During the intervention, 15 patients in group 1 (37.5%) and 26 patients in group 2 (65%) developed diarrhea, which was a significant difference (P = 0.02).Conclusions: Synbiotic is associated with a reduction in the incidence of VAP as well as a reduction in ICU stay and delayed VAP.","PeriodicalId":14342,"journal":{"name":"International Journal of Preventive Medicine","volume":"14 ","pages":"124"},"PeriodicalIF":1.7000,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10803674/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Preventive Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijpvm.ijpvm_329_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Ventilator-associated pneumonia (VAP) is one of the most common nosocomial infections. The role of probiotics in preventing VAP is still questionable. This study aimed at evaluating the effect of synbiotic FamiLact 2plus on the prevention of VAP in patients admitted to the intensive care unit (ICU).

Methods: A total of 80 mechanically ventilated patients were included and divided into two groups of 40. Group 1 received FamiLact 2plus, and group 2 received placebo. The outcome variables were compared, including the incidence of VAP, the time interval between the onset of ventilation and VAP, the duration of mechanical ventilation, and the length of stay in the ICU.

Results: VAP is documented in four patients (10%) in group 1 and 11 patients (27.5%) in group 2 (P = 0.045). The length of stay in the ICU in group 1 was significantly shorter than in group 2, and the time interval between the start of intubation and the onset of VAP in group 1 was longer than in the placebo group. During the intervention, 15 patients in group 1 (37.5%) and 26 patients in group 2 (65%) developed diarrhea, which was a significant difference (P = 0.02).

Conclusions: Synbiotic is associated with a reduction in the incidence of VAP as well as a reduction in ICU stay and delayed VAP.

查看原文本刊更多论文

评估合成益生菌在预防呼吸机相关肺炎中的作用：一项随机、三联盲、安慰剂对照临床试验。

背景：呼吸机相关肺炎（VAP）是最常见的院内感染之一。益生菌在预防 VAP 方面的作用尚存疑问。本研究旨在评估益生菌 FamiLact 2plus 对重症监护室（ICU）住院患者预防 VAP 的效果：方法：共纳入 80 名机械通气患者，将其分为两组，每组 40 人。第一组接受FamiLact 2plus，第二组接受安慰剂。对结果变量进行了比较，包括 VAP 发生率、开始通气与 VAP 之间的时间间隔、机械通气持续时间以及在重症监护室的住院时间：第 1 组有 4 名患者（10%）出现 VAP，第 2 组有 11 名患者（27.5%）出现 VAP（P = 0.045）。第 1 组患者在重症监护室的住院时间明显短于第 2 组，第 1 组患者从开始插管到发生 VAP 的时间间隔长于安慰剂组。在干预期间，第一组有15名患者（37.5%）和第二组有26名患者（65%）出现腹泻，差异显著（P = 0.02）：结论：合成益生菌可降低 VAP 的发生率，缩短重症监护室的住院时间，减少 VAP 的延迟。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Preventive Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

3.20

自引率

4.80%

发文量

107

期刊介绍： International Journal of Preventive Medicine, a publication of Isfahan University of Medical Sciences, is a peer-reviewed online journal with Continuous print on demand compilation of issues published. The journal’s full text is available online at http://www.ijpvmjournal.net. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. The journal will cover technical and clinical studies related to health, ethical and social issues in field of Preventive Medicine. Articles with clinical interest and implications will be given preference.